A stabilized synthetic analog of growth hormone–releasing hormone (GHRH) with a trans-3-hexenoic acid modification. This research peptide is used to investigate GHRH receptor dynamics and the modulation of the somatotropic axis in metabolic studies. For research use only. Not for human consumption.
Tesamorelin is a synthetic research peptide engineered as a stabilized analog of native growth hormone–releasing hormone (GHRH 1–44). Its structure includes a trans-3-hexenoic acid substitution at the second amino acid position, a modification designed to enhance peptide stability in experimental environments.
In preclinical and laboratory studies, Tesamorelin interacts with GHRH receptors on pituitary somatotroph cells, initiating intracellular signaling pathways associated with growth hormone synthesis and release. Because of its defined receptor activity and improved structural stability, Tesamorelin is frequently utilized in endocrine and metabolic research exploring GHRH receptor dynamics, peptide pharmacokinetics, and modulation of the somatotropic axis under controlled experimental conditions.
For research use only. Not for human consumption.
References
Falutz J, et al. Annals of Internal Medicine. 2010;152(5):323–331.
Gelato MC, et al. Journal of Clinical Endocrinology & Metabolism. 2005;90(9):5247–5253.
Stanley TL, et al. Journal of Clinical Endocrinology & Metabolism. 2014;99(3):E449–E458